3 completed, 1 recruiting. 4 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Completed 3, Recruiting 1 |
Follow poly ICLC: new trials by email Literature Review of poly ICLC trials Research Report on poly ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines. CD40.RBDv vaccine adjuvanted with Hiltonol®, CD40.Pan.CoV vaccine adjuvanted with Hiltonol®, Comirnaty® vaccine - Healthy Adults | Early Phase 1 | Recruiting | ANRS, Emerging Infectious Diseases | 48 | 2026-05-13 | 2026-06-02 |
| MUC1 Vaccine for Triple-negative Breast Cancer MUC-1 peptide vaccine, poly ICLC, MUC1 peptide-poly-ICLC adjuvant vaccine - Breast Cancer, Inflammatory Breast Cancer | Early Phase 1 | Completed | Joseph Baar, MD, PhD | 29 | 2009-08-19 | 2018-07-23 |
| HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas Peptide vaccine + Poly-ICLC - Astrocytoma, Oligoastrocytoma | Early Phase 1 | Completed | Ian F. Pollack, M.D. | 10 | 2009-04-01 | 2015-12-08 |
| Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas GAA/TT-peptide vaccine and poly-ICLC - Astrocytoma, Oligo-Astrocytoma | Early Phase 1 | Completed | Ian F. Pollack, M.D. | 13 | 2009-01-01 | 2019-08-30 |
Astrocytoma (2) · Breast Neoplasms (1) · Glioma (1) · Inflammatory Breast Neoplasms (1) · Neoplasms (1) · Oligodendroglioma (1) · Triple Negative Breast Neoplasms (1)
Ian F. Pollack, M.D. (2) · ANRS, Emerging Infectious Diseases (1) · Joseph Baar, MD, PhD (1)
United States (3) · France (1) · Switzerland (1)
Frank Lieberman, MD (2) · Joseph Baar, MD (1)
R21CA133859 (2)